Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| HUMAN GENOME SCIENCES INC | 174,484,221 | reported | 02 Aug 2012 | tx 5+75,055,830 |
| Progyny, Inc. | 6,238,244 | reported | 20 May 2020 | tx 3+9,821,190−13,821,190 |
| EPIX Pharmaceuticals, Inc. | 4,559,235 | reported | 29 Oct 2007 | tx 1+292,440 |
| Principia Biopharma Inc. | 2,982,855 | reported | 18 Oct 2019 | tx 14+3,013,570−21,399,081 |
| Anacor Pharmaceuticals Inc | 2,771,374 | reported | 24 Nov 2010 | tx 1+1,000,000 |
| Turning Point Therapeutics, Inc. | 2,253,660 | reported | 21 May 2020 | tx 8+2,268,660−6,420,068 |
| Spero Therapeutics, Inc. | 1,934,006 | reported | 17 Jul 2018 | tx 10+1,934,006−7,399,735 |
| BICYCLE THERAPEUTICS PLC | 1,910,609 | reported | 15 Jul 2020 | tx 8+1,915,275−1,075,116 |
| Fulcrum Therapeutics, Inc. | 1,785,714 | reported | 22 Jul 2019 | tx 2+1,785,714−12,500,000 |
| APPLIED GENETIC TECHNOLOGIES CORP | 1,436,448 | reported | 23 Feb 2015 | tx 11+1,989,598−66,557,478 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 02 Jul 2021 | CONVERSION | CVRx, Inc. | 14,917 | — | |
| 02 Jul 2021 | CONVERSION | CVRx, Inc. | 12,979 | — | |
| 02 Jul 2021 | CONVERSION | CVRx, Inc. | 1,505 | — | |
| 02 Jul 2021 | CONVERSION | CVRx, Inc. | 8,380 | — | |
| 02 Jul 2021 | PURCHASE | CVRx, Inc. | 275,000 | 18.00 USD | |
| 02 Jul 2021 | CONVERSION | CVRx, Inc. | 27,345 | — | |
| 02 Jul 2021 | CONVERSION | CVRx, Inc. | 635,646 | — | |
| 02 Jul 2021 | CONVERSION | CVRx, Inc. | 589,939 | 0.00 USD | deriv |
| 02 Jul 2021 | CONVERSION | CVRx, Inc. | 10,055,408 | 0.00 USD | deriv |
| 02 Jul 2021 | CONVERSION | CVRx, Inc. | 1,081,434 | 0.00 USD | deriv |
| 02 Jul 2021 | CONVERSION | CVRx, Inc. | 59,527 | 0.00 USD | deriv |
| 02 Jul 2021 | CONVERSION | CVRx, Inc. | 513,312 | 0.00 USD | deriv |
| 02 Jul 2021 | CONVERSION | CVRx, Inc. | 331,399 | 0.00 USD | deriv |
| 21 Jun 2021 | CONVERSION | Lyell Immunopharma, Inc. | 30,253,189 | — | |
| 21 Jun 2021 | CONVERSION | Lyell Immunopharma, Inc. | 30,253,189 | — | deriv |
| 20 May 2021 | SALE | Innoviva, Inc. | 32,005,260 | 12.25 USD | |
| 17 Feb 2021 | CONVERSION | Decibel Therapeutics, Inc. | 327,852 | — | |
| 17 Feb 2021 | CONVERSION | Decibel Therapeutics, Inc. | 247,324 | — | |
| 17 Feb 2021 | CONVERSION | Decibel Therapeutics, Inc. | 458,487 | — | |
| 17 Feb 2021 | PURCHASE | Decibel Therapeutics, Inc. | 150,000 | 18.00 USD | |
| 17 Feb 2021 | CONVERSION | Decibel Therapeutics, Inc. | 7,119,850 | — | deriv |
| 17 Feb 2021 | CONVERSION | Decibel Therapeutics, Inc. | 3,125,000 | — | deriv |
| 17 Feb 2021 | CONVERSION | Decibel Therapeutics, Inc. | 1,737,619 | — | deriv |
| 15 Jul 2020 | SALE | BICYCLE THERAPEUTICS PLC | 78 | 19.25 USD | |
| 15 Jul 2020 | SALE | BICYCLE THERAPEUTICS PLC | 3,069 | 19.40 USD |
1 purchase reported after at least 12 months of silence — most recent on 06 Nov 2017.